Ads
related to: prostate specific antigen in women over 70 percent of the body measurements- Dosing & Administration
Learn About Dosing Considerations
For This Targeted Treatment.
- Physician Resources
Download The Patient Brochure &
Other Helpful Resources Here.
- Access Information
Find Resources For Your Patients
With Advanced Prostate Cancer.
- Efficacy Information
Physicians, See How A Targeted
Treatment May Help Your Patients.
- Dosing & Administration
Search results
Results From The WOW.Com Content Network
Prostate-specific antigen (PSA), also known as gamma-seminoprotein or kallikrein-3 (KLK3), P-30 antigen, is a glycoprotein enzyme encoded in humans by the KLK3 gene. PSA is a member of the kallikrein -related peptidase family and is secreted by the epithelial cells of the prostate gland in men and the paraurethral glands in women.
A reference range is usually defined as the set of values 95 percent of the normal ... Prostate specific antigen (PSA) 40–49 years ... Higher in pregnant women [172 ...
Prostate-specific antigen. Prostate-specific antigen (PSA) is secreted by the epithelial cells of the prostate gland and can be detected in a sample of blood. [14] PSA is present in small quantities in the serum of men with healthy prostates, but is often elevated in the presence of prostate cancer or other prostate disorders. [15]
In some prostate cancers, PSMA is the second-most upregulated gene product, with an 8- to 12-fold increase over levels in noncancerous prostate cells. [19] Because of this high expression, PSMA is being developed as potential biomarker for therapy and imaging of some cancers. [ 20 ]
The standard definition of a reference range for a particular measurement is defined as the interval between which 95% of values of a reference population fall into, in such a way that 2.5% of the time a value will be less than the lower limit of this interval, and 2.5% of the time it will be larger than the upper limit of this interval, whatever the distribution of these values.
Prostate cancer staging is the process by which physicians categorize the risk of cancer having spread beyond the prostate, or equivalently, the probability of being cured with local therapies such as surgery or radiation. Once patients are placed in prognostic categories, this information can contribute to the selection of an optimal approach ...
Ad
related to: prostate specific antigen in women over 70 percent of the body measurements